MAP2K1 and cancer: Targeting MACC1 tyrosine phosphorylation using MEK1 inhibitors opens new options to intervene in MACC1-induced cell proliferation, motility, and metastasis aiming at the ultimate goal of personalized tailored therapies for inhibition of cancer progression and metastasis, resulting in improved patient survival.